<ENAMEX TYPE="ORGANIZATION">National Patent Development Corp</ENAMEX> said it plans to purchase as many as 200 000 common shares of its 81 controlled Interferon Sciences <ENAMEX TYPE="ORGANIZATION">Inc</ENAMEX> unit in periodic open market purchases The 200 000 shares are about 23 of Interferon s common shares outstanding excluding <ENAMEX TYPE="ORGANIZATION">National Patent</ENAMEX> s stake Noting the recent Food and <ENAMEX TYPE="ORGANIZATION">Drug Administration</ENAMEX> approval of Interferon s genital warts treatment <ENAMEX TYPE="ORGANIZATION">National Patent</ENAMEX> said it believes Interferon s stock is undervalued